TriangleNCT00262847 · CITED IN SOURCE DOCUMENTS
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2019-07-23
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Progression-free Survival
Overall Survival
Frequency and Severity (Grade 3 or Above) of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 3.0
Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients with a histologic diagnosis of epithelial ovarian cancer, peritoneal primary carcinoma or fallopian tube cancer; International Federation of Gynecology and Obstetrics (FIGO) stage III with any gross (macroscopic or palpable) residual disease or FIGO stage IV, defined surgically at the completion of initial abdominal surgery and with appropriate tissue available for histologic evaluation; the minimum surgery required was an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking; if additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the Gynecologic Oncology Group (GOG) Surgical Procedures Manual; however, the surgeon is not required to have performed all of the items contained in this section of the GOG Surgical Procedures Manual; those patients with stage III cancer in which the largest maximal diameter of any residual tumor implant at the completion of this initial surgery is no greater than 1 cm will be defined as "optimal;" all others will be defined as "suboptimal;" measurable disease on post-operative imaging studies is not required for eligibility * Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.); however, the histologic features of the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma; if doubt exists, it is recommended that the investigator should have the slides reviewed by an independent pathologist or, if necessary, the Pathology Co-Chair, prior to entry; patients may have co-existing fallopian tube carcinoma in-situ so long as the primary origin of invasive tumor is ovarian, peritoneal or fallopian tube * Absolute neutrophil count (ANC) greater than or equal to 1,500/µl equivalent to Common Toxicity Criteria for Adverse Events version (v)3.0 (CTCAE) grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factors * Platelets greater than or equal to 100,000/µl; (CTCAE grade 0-1) * Creatinine =\< 1.5 x institutional upper limit normal (ULN), CTCAE grade 1 * Bilirubin less than or equal to 1.5 x ULN (CTCAE grade 1) * Serum glutamic oxaloacetic transaminase (SGOT) and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1) * Neuropathy (sensory and motor) less than or equal to CTCAE grade 1 * Prothrombin time (PT) such that international normalized ratio (INR) is =\< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thrombo-embolus) and a partial thromboplastin time (PTT) \< 1.2 times the upper limit of normal * Patients with a GOG Performance Status of 0, 1, or 2 * Patients must be entered between 1 and 12 weeks after initial surgery performed for the combined purpose of diagnosis, staging and cytoreduction * Patients with measurable and non-measurable disease are eligible; patients may or may not have cancer-related symptoms * Patients who have met the pre-entry requirements * An approved informed consent and authorization permitting release of personal health information must be signed by the patient or guardian * Patients in this trial may receive ovarian estrogen +/- progestin replacement therapy as indicated at the lowest effective dose(s) for control of menopausal symptoms at any time, but not progestins for management of anorexia while on protocol directed therapy or prior to disease progression Exclusion Criteria: * Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly "tumors of low malignant potential") or recurrent invasive epithelial ovarian, primary peritoneal or fallopian tube cancer treated with surgery only (such as patients with stage Ia or Ib low grade epithelial ovarian or fallopian tube cancers) are not eligible; patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian tube cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor * Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease * Patients who have received prior chemotherapy for any abdominal or pelvic tumor including neo-adjuvant chemotherapy for their ovarian, primary peritoneal or fallopian tube cancer are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease * Patients who have received any targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian or peritoneal primary cancer * Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO grade 3 lesions * With the exception of non-melanoma skin cancer and other specific malignancies as noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this protocol therapy are excluded * Patients with acute hepatitis or active infection that requires parenteral antibiotics * Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations * Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels * Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study * Patients with clinically significant cardiovascular disease; this includes: * Uncontrolled hypertension, defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg * Myocardial infarction or unstable angina \< 6 months prior to registration * New York Heart Association (NYHA) grade II or greater congestive heart failure * Serious cardiac arrhythmia requiring medication; this does not include asymptomatic, atrial fibrillation with controlled ventricular rate * CTCAE grade 2 or greater peripheral vascular disease (at least brief (\< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit) * History of CVA within six months * Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * Patients with clinically significant proteinuria; urine protein should be screened by urine protein-creatinine ratio (UPCR); the UPCR has been found to correlate directly with the amount of protein excreted in a 24 hour urine collection; specifically, a UPCR of 1.0 is equivalent to 1.0 gram of protein in a 24 hour urine collection; obtain at least 4 ml of a random urine sample in a sterile container (does not have to be a 24 hour urine); send sample to lab with request for urine protein and creatinine levels \[separate requests\]; the lab will measure protein concentration (mg/dL) and creatinine concentration (mg/dL); the UPCR is derived as follows: protein concentration (mg/dL)/creatinine (mg/dL); patients must have a UPCR \< 1.0 to allow participation in the study * Patients with or with anticipation of invasive procedures as defined below: * Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab/placebo therapy (cycle 2) * Major surgical procedure anticipated during the course of the study; this includes, but is not limited to abdominal surgery (laparotomy or laparoscopy) prior to disease progression, such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery; please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures * Core biopsy, within 7 days prior to the first date of bevacizumab/placebo therapy (cycle 2) * Patients with GOG Performance Grade of 3 or 4 * Patients who are pregnant or nursing; bevacizumab should not be administered to nursing women; patients of childbearing potential must agree to use contraceptive measures during study therapy and for at least six months after completion of bevacizumab therapy * Patients who have received prior therapy with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumab * Patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and/or nutrition * Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator should feel free to consult the study chair or study co-chairs for uncertainty in this regard
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- Other: Placebo
- Other: Quality-of-Life Assessment
- label
- Arm I (placebo, paclitaxel, carboplatin)
- type
- ACTIVE_COMPARATOR
- description
- Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Biological: Bevacizumab
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- Other: Placebo
- Other: Quality-of-Life Assessment
- label
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- type
- EXPERIMENTAL
- description
- Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Biological: Bevacizumab
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- Other: Quality-of-Life Assessment
- label
- Arm III (paclitaxel, carboplatin, bevacizumab)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- Arm III (paclitaxel, carboplatin, bevacizumab)
- description
- Given IV
- name
- Bevacizumab
- other Names
- Anti-VEGF
- Anti-VEGF Humanized Monoclonal Antibody
- Anti-VEGF rhuMAb
- Avastin
- Bevacizumab Biosimilar BEVZ92
- Bevacizumab Biosimilar BI 695502
- Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer
- Recombinant Humanized Anti-VEGF Monoclonal Antibody
- rhuMab-VEGF
- type
- BIOLOGICAL
- arm Group Labels
- Arm I (placebo, paclitaxel, carboplatin)
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- Arm III (paclitaxel, carboplatin, bevacizumab)
- description
- Given IV
- name
- Carboplatin
- other Names
- Blastocarb
- Carboplat
- Carboplatin Hexal
- Carboplatino
- Carbosin
- Carbosol
- Carbotec
- CBDCA
- Displata
- Ercar
- JM-8
- Nealorin
- type
- DRUG
- arm Group Labels
- Arm I (placebo, paclitaxel, carboplatin)
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- Arm III (paclitaxel, carboplatin, bevacizumab)
- description
- Correlative studies
- name
- Laboratory Biomarker Analysis
- type
- OTHER
- arm Group Labels
- Arm I (placebo, paclitaxel, carboplatin)
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- Arm III (paclitaxel, carboplatin, bevacizumab)
- description
- Given IV
- name
- Paclitaxel
- other Names
- Anzatax
- Asotax
- Bristaxol
- Praxel
- Taxol
- Taxol Konzentrat
- type
- DRUG
- arm Group Labels
- Arm I (placebo, paclitaxel, carboplatin)
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- description
- Given IV
- name
- Placebo
- other Names
- placebo therapy
- PLCB
- sham therapy
- type
- OTHER
- arm Group Labels
- Arm I (placebo, paclitaxel, carboplatin)
- Arm II (placebo, paclitaxel, carboplatin, bevacizumab)
- Arm III (paclitaxel, carboplatin, bevacizumab)
- description
- Ancillary studies
- name
- Quality-of-Life Assessment
- other Names
- Quality of Life Assessment
- type
- OTHER
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- DOUBLE
- who Masked
- PARTICIPANT
- INVESTIGATOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 1873
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Median progression-free survival (PFS). Onset of progression could be based on radiographic (RECIST) criteria or rising CA-125 (GCIG criteria).
- measure
- Progression-free Survival
- time Frame
- From study entry until first disease progression, death or date of last contact, up to 6 years
- secondary Outcomes
- description
- Median overall survival (OS)
- measure
- Overall Survival
- time Frame
- From study entry to death or last contact, up to 6 years
- description
- Eligible and Evaluable patients
- measure
- Frequency and Severity (Grade 3 or Above) of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 3.0
- time Frame
- Up to 5 years
- description
- Estimated least squares means from a mixed module of Quality of Life (QOL) scores at each assessment point, adjusted for baseline score and patient's age. Note: The range of possible scores of the FACT-O TOI is 0 - 104 for all treatment groups and at all visits. A higher score indicates better QOL. Baseline mean scores are raw means.
- measure
- Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)
- time Frame
- At baseline, 9, 18, 36, 60, and 84 weeks
Full study description
- brief Summary
- This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer.
- detailed Description
- PRIMARY OBJECTIVE: I. To determine if the addition of 5 concurrent cycles of bevacizumab to 6 cycles of standard therapy (carboplatin and paclitaxel) (Arm II) increases the duration of progression-free survival (PFS) when compared to 6 cycles of standard therapy alone (Arm I) in women with newly diagnosed stage III (with any gross residual disease) and stage IV, epithelial ovarian, peritoneal primary or fallopian tube cancer. II. To determine if the addition of 5 concurrent cycles of bevacizumab plus extended bevacizumab for 16 cycles beyond the 6 cycles of standard therapy (carboplatin and paclitaxel) (Arm III) increases progression-free survival when compared to 6 cycles of standard therapy (Arm I) in women with newly diagnosed stage III (with any gross residual disease) and stage IV, epithelial ovarian, peritoneal primary or fallopian tube cancer. SECONDARY OBJECTIVES: I. In the event that both Arm II and Arm III regimens are superior to the Arm I regimen with respect to progression-free survival, to determine whether the Arm III regimen prolongs progression-free survival when compared to the Arm II regimen. II. To determine whether the Arm II or Arm III regimen increases the duration of overall survival when compared with the Arm I regimen. III. To compare each of the experimental regimens to the Arm I regimen with respect to the incidence of severe toxicities or serious adverse events. IV. To determine the impact on Quality of Life (QOL, as measured by the Functional Assessment of Cancer Therapy-Ovarian \[FACT-O\] trial outcome index \[TOI\]) following treatment with the above regimens. TERTIARY OBJECTIVES: I. To assess the relationship between angiogenic markers and clinical outcome including tumor response, progression-free survival and overall survival in patients randomized to standard cytotoxic chemotherapy (paclitaxel and carboplatin) without bevacizumab, with concurrent bevacizumab or with extended bevacizumab. II. To assess the predictive value of a set of genes whose expression correlates with survival of patients with stage III (with any gross residual disease) and stage IV, epithelial ovarian, peritoneal primary or fallopian tube cancer. III. To bank whole blood for research. IV. To determine if genetic variations in genes associated with essential hypertension including WNK lysine deficient protein kinase 1 (WNK1), G protein-coupled receptor kinase 4 (GRK4) and kallikrein B (KLKB1) predict which patients are likely to develop bevacizumab-induced hypertension. OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity. ARM III: Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Source references
- references
- citation
- Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
- pmid
- 37185961
- type
- DERIVED
- citation
- You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17.
- pmid
- 36252167
- type
- DERIVED
- citation
- Morgan RD, Ferreras C, Peset I, Avizienyte E, Renehan AG, Edmondson RJ, Murphy AD, Nicum S, Van Brussel T, Clamp AR, Lambrechts D, Zhou C, Jayson GC. c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Med. 2022 Feb 11;20(1):59. doi: 10.1186/s12916-022-02270-y.
- pmid
- 35144591
- type
- DERIVED
- citation
- Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.
- pmid
- 31216226
- type
- DERIVED
- citation
- Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.
- pmid
- 29550184
- type
- DERIVED
- citation
- Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan;27(1):114-21. doi: 10.1093/annonc/mdv500. Epub 2015 Oct 20.
- pmid
- 26487588
- type
- DERIVED
- citation
- Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013 Mar;128(3):573-8. doi: 10.1016/j.ygyno.2012.11.038. Epub 2012 Dec 4.
- pmid
- 23219660
- type
- DERIVED
- citation
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.
- pmid
- 22204724
- type
- DERIVED
- citation
- Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
- pmid
- 21941283
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-0a6e30f211801cafb7a3
- requested nct id
- NCT00262847
- primary nct id
- NCT00262847
- source kind
- fda_spl_label
- source record id
- 8debebf6-af94-4ba7-8d67-c801f4ea27eb
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- e43f924773111e70829ec549308cb70a1281f132317d326a882cfd5271678396
- payload
- application numbers
- BLA125085
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-0a6e30f211801cafb7a3
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00262847
- occurrences
- context exact
- udy GOG-0218 The safety and efficacy of Avastin were evaluated in a multicenter, randomized, double-blind, placebo controlled, three arm study [Study GOG-0218 (NCT00262847)] evaluating the effect of adding Avastin to carboplatin and paclitaxel for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube o
- end
- 19371
- exact text
- NCT00262847
- start
- 19360
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/24/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 8debebf6-af94-4ba7-8d67-c801f4ea27eb
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6f9f86027b6f32969be7f30286f48e96e380fd91a3cb2490b51001f709a7db71
- spl effective time
- 20250106
- spl set id
- 939b5d1f-9fb2-4499-80ef-0607aa6b114e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-0ecdb8c14f3ccc0c1976
- requested nct id
- NCT00262847
- primary nct id
- NCT00262847
- source kind
- fda_spl_label
- source record id
- 598b7687-6daa-2ce7-e063-6394a90ab429
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 50585e817436e24d1c7325440600db21a8cded62f9efba8a58e5de04a21b207d
- payload
- application numbers
- BLA761268
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-0ecdb8c14f3ccc0c1976
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00262847
- occurrences
- context exact
- OG-0218 The safety and efficacy of bevacizumab were evaluated in a multicenter, randomized, double-blind, placebo controlled, three arm study [Study GOG-0218 ( NCT00262847 )] evaluating the effect of adding bevacizumab to carboplatin and paclitaxel for the treatment of patients with stage III or IV epithelial ovarian, fallopian t
- end
- 19703
- exact text
- NCT00262847
- start
- 19692
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/78/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 598b7687-6daa-2ce7-e063-6394a90ab429
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 20f4d916b986722fb555e4c9410051bc1746100f6c73529af41036961c7d881c
- spl effective time
- 20260821
- spl set id
- 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-3fad3c4969ef1f280315
- requested nct id
- NCT00262847
- primary nct id
- NCT00262847
- source kind
- fda_spl_label
- source record id
- 8f385b9e-2699-46a0-8c5f-ec1d86cd609d
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 24ff450a15824b6b914cc0bb9150d4be783b227e1c4ab3a29525c5d6b8bb2929
- payload
- application numbers
- BLA761099
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-3fad3c4969ef1f280315
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00262847
- occurrences
- context exact
- GOG-0218 The safety and efficacy of bevacizumab were evaluated in a multicenter, randomized, double-blind, placebo-controlled, three arm study [Study GOG-0218 (NCT00262847)] evaluating the effect of adding bevacizumab to carboplatin and paclitaxel for the treatment of patients with stage III or IV epithelial ovarian, fallopian tu
- end
- 19685
- exact text
- NCT00262847
- start
- 19674
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/27/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 8f385b9e-2699-46a0-8c5f-ec1d86cd609d
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 774cfec5b812453dac521297deff828caeb90e4c09011e2ec66273f66c607f0b
- spl effective time
- 20260721
- spl set id
- aa27acbd-d117-4350-aeee-17bc2e2c0ca4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5b06919275c8c7b2dc49
- requested nct id
- NCT00262847
- primary nct id
- NCT00262847
- source kind
- fda_spl_label
- source record id
- ea079b8e-24b7-4e03-8340-8078f30f6d98
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 85ad537e7e5d25e0d10e988c6a5971459bba546bc7b32ad129f922f90df92c5d
- payload
- application numbers
- BLA761028
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5b06919275c8c7b2dc49
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00262847
- occurrences
- context exact
- GOG-0218 The safety and efficacy of bevacizumab were evaluated in a multicenter, randomized, double-blind, placebo controlled, three arm study [Study GOG-0218 (NCT00262847)] evaluating the effect of adding bevacizumab to carboplatin and paclitaxel for the treatment of patients with stage III or IV epithelial ovarian, fallopian tu
- end
- 19729
- exact text
- NCT00262847
- start
- 19718
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/79/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ea079b8e-24b7-4e03-8340-8078f30f6d98
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- bbf2f2af7cb8babda09095a78b354d15a500aba442759b04c1595566b0870385
- spl effective time
- 20260623
- spl set id
- 0a562b4e-67ce-4bab-852c-d9ee71e55fb8
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-7274f0ffb850b19b4668
- requested nct id
- NCT00262847
- primary nct id
- NCT00262847
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
- payload sha256
- cbe3681fd73983eea9ded80b4d5003cfb888b6b28ae3c8b3effec6586b3fc91c
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-7274f0ffb850b19b4668
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00262847
- occurrences
- context exact
- <td>Est 42</td> </tr> <tr> <td rowspan="3"> <strong> <a href="/clinicaltrials/NCT00262847">GOG-218</a> </strong> </td> <td> <strong>Paclitaxel (175 mg/m<span class="sup">2</span>) a
- end
- 165771
- exact text
- NCT00262847
- start
- 165760
- context exact
- merican Society of Clinical Oncology.[<a href="#cit/section_7.45">45</a>]</p> <p id="_760" tabindex="-1">Two phase III trials (<a href="/clinicaltrials/NCT00262847">GOG-0218</a> [NCT00262847] and <a href="/clinicaltrials/NCT00483782">ICON7 </a> [NCT00483782]) have evaluated the role of bevacizumab in first-line therapy fo
- end
- 184315
- exact text
- NCT00262847
- start
- 184304
- context exact
- Oncology.[<a href="#cit/section_7.45">45</a>]</p> <p id="_760" tabindex="-1">Two phase III trials (<a href="/clinicaltrials/NCT00262847">GOG-0218</a> [NCT00262847] and <a href="/clinicaltrials/NCT00483782">ICON7 </a> [NCT00483782]) have evaluated the role of bevacizumab in first-line therapy for ovarian epithelial cancer
- end
- 184342
- exact text
- NCT00262847
- start
- 184331
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/ff9ceeeae0fbdc33fd.html
- source file sha256
- d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:22:10.059252+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 2a71979c192f62071168507c9e3b23e31a4e8fe2e21ca0f7ee294555ff0250c9
- source title
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 14, 2025
- datetime
- 2025-05-14T12:00:00Z
- display
- May 14, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-c8f705f73a1c916f6b9f
- requested nct id
- NCT00262847
- primary nct id
- NCT00262847
- source kind
- fda_spl_label
- source record id
- 2644fd0e-5b94-9120-bdb1-e275d982b249
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- f8b0eb249a8fd88709b674cb234de013fa516be5e3dae433b39ba0065d318e97
- payload
- application numbers
- BLA761175
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-c8f705f73a1c916f6b9f
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00262847
- occurrences
- context exact
- GOG-0218 The safety and efficacy of bevacizumab were evaluated in a multicenter, randomized, double-blind, placebo controlled, three arm study [Study GOG-0218 (NCT00262847)] evaluating the effect of adding bevacizumab to carboplatin and paclitaxel for the treatment of patients with stage III or IV epithelial ovarian, fallopian tu
- end
- 20243
- exact text
- NCT00262847
- start
- 20232
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/34/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 2644fd0e-5b94-9120-bdb1-e275d982b249
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e21069a0948bbce06a85786ddbbc2839d4f9236f5865abba3e3379c45bd1d271
- spl effective time
- 20260311
- spl set id
- 70ab1de6-fb68-aee4-a6cb-f9a0f146687f
Preserved source evidence · Not medical advice